FDA Grants Priority Review to Merck's Application for KEYTRUDA Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1
Benzinga_Newsdesk